Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Conference Call March 6, 2024 8:00 AM ET
Company Participants
Bennett Watson - Investor Relations, ICR Westwicke
Dan Barber - Chief Executive Officer
Ernie Toth - Chief Financial Officer
Carl Kraus - Chief Medical Officer
Conference Call Participants
François Brisebois - Oppenheimer
Jason Butler - Citizens JMP Securities
Andreas Argyrides - Wedbush
Thomas Flaten - Lake Street Capital Markets
Ram Selvaraju - H.C. Wainwright
James Molloy - Alliance Global Partners
Operator
Good morning, and welcome to Aquestive Therapeutics Fourth Quarter and Full Year 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this call will be recorded.
I would now like to introduce your host for today's conference call, Bennett Watson of ICR Westwicke Investor Relations. Please go ahead.
Bennett Watson
Thank you, operator. Good morning, and welcome to today's call.
On today's call, I'm joined by Dan Barber, Chief Executive Officer, and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance for the fourth quarter and year-end 2023, followed by a Q&A session. During the Q&A session, the team will be joined by Dr. Carl Kraus, Chief Medical Officer, and Dr. Stephen Wargacki, Senior Vice President, Research and Development.
As a reminder, the company's remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today's call will be made available on Aquestive's website within the Investors section shortly following the conclusion of this call.
To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of fourth quarter and year-end 2023 results. A description of these measures along with a reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive's website.
During the call, the company will be making forward-looking statements. We remind you of the company's safe harbor language as outlined in yesterday's earnings release as well as the risks and uncertainties affecting the company as described in the Risk Factors section and in other sections included in the company's annual report on Form 10-K filed with the Securities and Exchange Commission on March 5, 2024.
As with any pharmaceutical company, with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company's business and the development, regulatory approval and commercialization of its products and other matters related to operations. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. Actual results may differ materially from these statements.